Personalized digital therapeutics
for the treatment of diseases
with high unmet medical need
OUR STORY
WELT was founded in 2016 as a spin-off of SAMSUNG to explore the intersection of healthcare and technology
MISSION
We create personalized digital therapeutics that combine our expertise in sensor and digital biomarker technologies with therapeutic contents for the treatment of diseases with high unmet medical need
DTx Leader in Korea
WELT served as an industry advisor for the Ministry of Food
and
Drug Safety (KFDA) on digital therapeutics
WELT partnered with multiple government institutions
re: adoption and implementation of digital therapeutics in Korea
WELT co-chairs the DTA APAC Working Group to promote
the industry in the region
PRODUCT PIPELINE
INVESTORS & PARTNERS
At WELT, we believe that an ideal digital therapeutics company should strategize like pharma, execute like tech company, and build a culture resembling that of gaming company. Our group of investors and partners reflects that belief.
INVESTORS
PARTNERS
